How We WorkOrder NowSupport Privacy

Stocks Under Consideration by FMS – BMY, MRK, JNJ, LLY

on 16/11/2012

NEW YORK, NOVEMBER 16, 2012 — (Net PR News) — Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (AZN) jointly reported that their type II diabetes candidate, Forxiga (dapagliflozin) has recognized European sanction. The European Commission (EC) permitted the once-daily oral product for improving glycemic control in type II diabetes patients above 18 years along with lifestyle management and other glucose-lowering products, such as insulin. Forxiga can be used as a monotherapy in patients who are intolerant to metformin.

Bristol Myers Squibb Co. (NYSE:BMY) closed at the price of $30.81 whereas its previous closing was recorded at $31.48. The stock traded within the day range of $30.64 – $31.38 and 52week range remained in between $30.10 – $36.34. The stock has the total volume of 23.03 million shares; its average volume was 10.30 million shares for the last 3 months as compared to the market capitalization of $50.86 billion.

Bristol Myers Squibb Co. (NYSE:BMY) has the total of 1.65 billion outstanding shares as compared to 1.65 billion shares that were floated in the market.

How Should Investors Trade BMY Now? Don’t Trade BMY until you Read this Trend Analysis Report

Merck & Co (NYSE:MRK) presented new data at the 11th International Congress on HIV and Drug Therapy in HIV Infection (HIV 11) in Glasgow, Scotland, from a post-hoc, subgroup analysis of three double-blind clinical trials, which found Isentress (raltegravir) which demonstrated consistent long-term viral suppression and a well established safety profile in adult patients co-infected with HIV-1 and hepatitis C (HCV) and/or hepatitis B (HBV) when compared to adult patients with HIV-1 at 240 weeks.

Merck & Co., Inc. (NYSE:MRK) percentage change declined -0.58% to close at $42.80 with the total traded volume of 12.28 million shares, more than the average volume of 11.09 million.

Its market capitalization is $130.35 billion and EPS was $2.20. Its beta value stands at 0.64 times. Its shares were trading within the range of $42.55-$43.14 while its opening price was $42.96.

How Should Investors React To MRK Now? Find Out in this Trend Analysis Report

Johnson & Johnson (NYSE:JNJ), plans to start on a one-stop database of global clinical trial sites, with collaboration from Merck & Co Inc and Eli Lilly & Co, intended at streamlining paperwork and speeding the process for testing new drugs.

The partners have begun securing approval from as many as 100,000 clinical investigators to enter their details into the database, Andreas Koester, head of clinical trial innovation/external alliances at J&J’s Janssen unit, said in a telephone interview.

Johnson & Johnson (NYSE:JNJ) moved down -0.29% to close at $69.07. Its total traded volume during the last trading session was 11.80 million shares. The Company’s 5 years revenue rate remained 4.05%. The total market capitalization is $190.43 billion. It gained 13.58% return on Equity, 8.82% return on Investment and 7.08% return on Assets.

Get a free report and detailed analysis on JNJ Click Here to read

Eli Lilly & Co. (NYSE:LLY) dropped -0.56% to close at $45.96 with the total traded volume of 6.86 million shares with the average volume of 10.50 million. Its shares were trading within the range of $44.88- $46.41 while its opening price was $46.17. Its market capitalization is $53.33 billion. Its stock price 52 weeks low was $35.46 and 52 weeks high price was $53.99.

Eli Lilly & Co. was founded by Eli Lilly in 1876, and is now the 10th largest pharmaceutical company in the world. They have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs.

Will LLY continue moving lower? Find out where LLY is headed next with a FREE TREND ANALYSIS REPORT


About Fast Moving Stocks is engaged in providing valuable ideas and news information on U.S. stocks on a regular basis. provides detailed research guides on small cap and large cap stocks, helping investors in making wise stock market investments decisions through its free e-newsletter subscribers.


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does not expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.


Albert Willson

Source: Fast Moving Stock Posted Fri, November 16, 2012 14:15 - Permalink